MAPT and Alzheimer disease: The other group of patients with analysis of biomarkers comprised patients in whom at least one biomarker was compatible with AD (DD-BM+; Abeta1,42 ≤ 550 pg/ml, total-tau-protein above diagnostic threshold (≥ 300 pg/ml), or 18F-FDG-PET suggestive of AD, or amyloid-PET positive).